H.C. Wainwright analyst Robert Burns raised the firm’s price target on Revolution Medicines (RVMD) to $73 from $72 and keeps a Buy rating on the shares following the Q3 report. The firm says new clinical data support the thesis that elironrasib addresses resistance mechanisms to first-generation KRAS inhibitors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines Reports Q3 2025 Financial Results
- Revolution Medicines: Strategic Advancements and Promising Pipeline in PDAC Treatment Justify Buy Rating
- Revolution Medicines: Promising Growth Trajectory with Strong Financial Health and Strategic Advancements
- Revolution Medicines reiterates FY25 GAAP net loss guidance
- Revolution Medicines reports Q3 EPS ($1.61), consensus ($1.41)